Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research report sent to investors on Monday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Performance

Lipocine stock opened at $2.84 on Monday. Lipocine has a 1 year low of $2.75 and a 1 year high of $11.79. The firm’s 50-day moving average is $3.51 and its 200-day moving average is $4.45. The company has a market cap of $15.19 million, a P/E ratio of -3.74 and a beta of 1.51.

Hedge Funds Weigh In On Lipocine

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC boosted its stake in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,464 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,248 shares during the quarter. Geode Capital Management LLC owned approximately 1.07% of Lipocine worth $280,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.